Abstract

The use of bioprostheses for heart valve therapy has gradually evolved over several decades and both surgical and transcatheter devices are now highly successful. The rapid expansion of the transcatheter concept has clearly placed a significant onus on the need for improved production methods, particularly the pre-treatment of bovine pericardium. Two of the difficulties associated with the biocompatibility of bioprosthetic valves are the possibilities of immune responses and calcification, which have led to either catastrophic failure or slow dystrophic changes. These have been addressed by evolutionary trends in cross-linking and decellularization techniques and, over the last two decades, the improvements have resulted in somewhat greater durability. However, as the need to consider the use of bioprosthetic valves in younger patients has become an important clinical and sociological issue, the requirement for even greater longevity and safety is now paramount. This is especially true with respect to potential therapies for young people who are afflicted by rheumatic heart disease, mostly in low- to middle-income countries, for whom no clinically acceptable and cost-effective treatments currently exist. To extend longevity to this new level, it has been necessary to evaluate the mechanisms of pericardium biocompatibility, with special emphasis on the interplay between cross-linking, decellularization and anti-immunogenicity processes. These mechanisms are reviewed in this paper. On the basis of a better understanding of these mechanisms, a few alternative treatment protocols have been developed in the last few years. The most promising protocol here is based on a carefully designed combination of phases of tissue-protective decellularization with a finely-titrated cross-linking sequence. Such refined protocols offer considerable potential in the progress toward superior longevity of pericardial heart valves and introduce a scientific dimension beyond the largely disappointing ‘anti-calcification’ treatments of past decades.

Highlights

  • Valvular Heart Disease (VHD) affects large numbers of individuals, perhaps as many as 100 million diagnosed annually, world-wide [1]

  • The second was associated with the development of transcatheter techniques for valve replacement (TAVR) [13, 14], which obviated the need for open-heart surgery

  • Khorramirouz et al showed the presence of a variety of CD+ inflammatory cells in decellularized porcine pericardium implanted subcutaneously in rats [43], which is a widely used animal model for the study of calcification [44], but obviously this does not represent a clinically realistic situation related to heart valves

Read more

Summary

INTRODUCTION

Valvular Heart Disease (VHD) affects large numbers of individuals, perhaps as many as 100 million diagnosed annually, world-wide [1]. Various algorithms have been published that may inform the selection of prostheses by clinicians [21, 22], one of the most important factors being the patient’s age as a marker of their chances of death (by non-valve-related causes) before pericardium dysfunction This is enshrined in the ESC/EACTS 2017 guidelines on the management of VHD [23] which states that “A bioprosthesis should be considered in patients > 65 years of age for a prosthesis in the aortic position, or > 70 years of age in a mitral position, or those with a life expectancy lower than the presumed durability of the bioprosthesis.”. Emphasis is given to the ability to use TAVR valves in the low- to middle-income countries mentioned above, where valve longevity in young RHD patients is a critical factor

THE STRUCTURE AND PROPERTIES OF NATURAL PERICARDIUM
General Overview
Denaturation and Degradation
TREATMENT OF XENOGENEIC PERICARDIUM BEFORE CLINICAL IMPLANTATION
Electroporation Biological methods Trypsin
Can also damage the ECM
Effective lyses of cells but does not remove the cellular debris
Findings
Overview and Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call